Nervonik
PrivateLast Round
Series B
Apr 27, 2026
Est. Valuation
$121M
Total Funding Raised
$74.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nervonik operates in Healthcare & Life Sciences and is based in Los Angeles, California. Its latest recorded funding round was a Series B round in April 2026.
Nervonik is a medical technology company that develops miniaturized, power-efficient neuromodulation implants and peripheral nerve stimulation systems for the treatment of chronic neuropathic pain.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nervonik Comparables
Compare Nervonik with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuros Medical | 87% | |
| SPR Therapeutics | 84% | |
| Curonix | 84% |
For institutional investors. Book with your work email.
Nervonik Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 27, 2026 | ||||
| Series A | Mar 4, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nervonik Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amzak Health | Series B |
| U.S. Venture Partners | Series B, Series A |
| Foothill Ventures | Series A, Series B |
| Seraph Group | Convertible Debt, Seed |
| Joyance Partners | Convertible Debt, Seed |
| ShangBay Capital | Convertible Debt, Series B, Seed |
| Lumira Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 13, 2026
Open roles increased to 3, 3x the trailing average.
- Apr 27, 2026
$53M round led by Amzak Health.
For institutional investors. Book with your work email.
Nervonik Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nervonik's valuation, stock price, and market status.
Is Nervonik a public or private company?
Nervonik is a private company.
What is the current stock price of Nervonik?
Nervonik is a private company, so its shares have no public market price. Caplight tracks Nervonik's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nervonik worth (valuation)?
Nervonik's valuation is estimated at $121.0M based on funding round data.
Can I buy Nervonik stock?
Nervonik shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nervonik's last funding round?
Nervonik's most recent funding round was Series B on April 27, 2026.
Who are the main investors in Nervonik?
Key investors in Nervonik include Amzak Health, U.S. Venture Partners.
Will Nervonik IPO soon?
No public IPO plans have been announced for Nervonik.
How can I track Nervonik secondary market activity?
Caplight tracks bids, offers, and trades in Nervonik's shares on secondary markets.